Trial Profile

A Two-period Study in Healthy Male Participants to Determine the Pharmacokinetics, Balance/Excretion, and Metabolism of [14C]-Linerixibat Following a Single Intravenous Radiolabeled Microtracer Dose (Concomitant With a Non-radiolabeled Oral Dose) and a Single Oral Radiolabeled Dose

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linerixibat (Primary) ; Linerixibat (Primary)
Indications Cholestasis; Primary biliary cirrhosis; Pruritus; Type 2 diabetes mellitus
Focus Pharmacokinetics
Sponsors GlaxoSmithKline

08 Oct 2021 Results assessing the the pharmacokinetics, absorption, distribution, metabolism, and excretion of [14C]-linerixibat in humans, published in the Drug Metabolism and Disposition.
10 Sep 2019 Status changed from active, no longer recruiting to completed.
12 Aug 2019 Status changed from not yet recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com